Abstract:Atherosclerosis is the leading cause of death in western countries. Lipoprotein metabolism is closely related with the disease. ApoB-containing lipoproteins (BLp) are atherogenic particles, while, high density lipoproteins (HDL) are anti-atherogenic. Phospholipids Transfer Protein (PLTP) activity has important impact on BLp and HDL homeostasis. Animal studies, including general knock out (KO) and transgenic approaches, have shown pro-atherogenic properties for PLTP. However, the tissue specific function of PLTP remains mostly unknown. To address the impact of liver-specific expression of PLTP on lipoprotein metabolism, we have created two mouse models which either express PLTP specifically in the liver on a PLTP-null background or do not express PLTP in the liver (liver-specific PLTP KO) in a wild type background. In both models, our findings show that liver-specific PLTP is responsible for 25-30% of total plasma PLTP activity. Moreover, liver-specific PLTP expression model shows a remarkable increase in plasma levels of BLp, whereas liver-specific PLTP KO mice show significant reduction of BLp in plasma in compare to control group. These results further show the significant contribution of PLTP in BLp production. We also found that HDL levels are slightly increased in the first model, while in liver-specific PLTP KO animals HDL levels are significantly decreased. In order to unravel the mechanism, we evaluated the apoB and triglyceride production rates after blocking the clearance of the particles. We found that liver-specific PLTP increases apoB (both apo48 and apoB100) and triglyceride (TG) secretion rates. Additionally, the study of the hepatocyte microsomal luminal content lipidation in the first model showed that in the presence of PLTP BLp lipidation, which reflects as higher level of TG in microsomal luminal content, is significantly higher than the control group. Our results indicate that liver-generated PLTP promotes atherogenic lipoprotein production and provides a rationale for liver-specific PLTP inhibition as a therapeutical approach for the treatment of atherosclerosis.

Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Liver-Specific Phospholipid Transfer Protein Deficiency Reduces High-Density Lipoprotein and Non–High-Density Lipoprotein Production in Mice

Abstract 330: Liver-Specific Phospholipids Transfer Protein Activity Has Significant Contribution in Hepatocyte Apob-Containing Lipoprotein Production and in Plasma Lipoprotein Metabolism

Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo

Targeted Mutation of Plasma Phospholipid Transfer Protein Gene Markedly Reduces High-Density Lipoprotein Levels.

Increased Prebeta-High Density Lipoprotein, Apoai And Phospholipid In Mice Expressing The Human Phospholipid Transfer Protein And Apoai Transgenes

Phospholipid Transfer Protein Gene Knock-out Mice Have Low High Density Lipoprotein Levels, Due to Hypercatabolism, and Accumulate Apoa-Iv-rich Lamellar Lipoproteins.

Phospholipid Transfer Protein (Pltp) Deficient Mice Absorb Less Cholesterol

Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants.

Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency

Increased Atherosclerotic Lesions in ApoE Mice with Plasma Phospholipid Transfer Protein Overexpression

Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate

Regulation of Plasma Lipid Homeostasis by Hepatic Lipoprotein Lipase in Adult Mice.

The Effect of Phospholipid Transfer Protein on Lipoprotein Metabolism and Atherosclerosis

Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein

Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway Through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants*

Phospholipid Transfer Protein (PLTP) Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance.

Pharmacologic Inhibition of Phospholipid Transfer Protein Activity Reduces Apolipoprotein-B Secretion from Hepatocytes.

Effects of Phospholipid Transfer Protein Overexpression on Content of Sphingosine-1-phosphate in Mouse Lipoprotein

Macrophage Phospholipid Transfer Protein Contributes Significantly To Total Plasma Phospholipid Transfer Activity And Its Deficiency Leads To Diminished Atherosclerotic Lesion Development

Abstract 19705: PLTP Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance